The Congressional Budget Office (CBO) put out a draft of a paper where it notes calculations regarding Medicare drug prices. Notably, reports from ICER (Institute for Clinical and Economic Review) hold substantial weight. Should the federal government move to regulate drug prices, this institution could carry even more clout in the future.
According to John Wilkerson of Inside Health Policy, “The CBO paper is an indication of how powerful the Institute for Clinical & Economic Review could become if the government moves to a system that sets prices for drugs based on their value to the health care system.” Read more here.
(Source: John Wilkerson, Inside Health Policy, 2/8/21)